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ABSTRACT
Introduction. Deep brain stimulation (DBS) therapy for Parkinson’s Disease (PD) and dystonia is associated with the possibility 
of both minor and major complications. One possible side effect is the depletion of implantable pulse generator (IPG) battery 
and the associated sudden recurrence of PD or dystonia symptoms, which can be potentially life-threatening. Delayed or post-
poned outpatient visits due to COVID -19 may be a risk factor of battery end-of-life consequences. 
Objective. To analyse the clinical outcomes in reported PD and dystonia patients treated with DBS, who, as a result of the 
sudden depletion of the neurostimulator battery, developed life-threatening symptoms. 
Materials and methods. The databases of PubMed, Scopus, EMBASE and Google Scholar were searched using pre-established 
criteria. 
Results. A total of 244 articles was found, of which 12 met the adopted criteria. Selected papers presented a total of 17 case 
reports of DBS-treated patients — 11 with PD, and six with dystonia — who had depleted IPG batteries and due to rapid worse-
ning of PD/dystonia symptoms required urgent hospital admission. IPG battery replacement was the only effective treatment 
in the majority of cases. 
Conclusions. IPG battery depletion can result in fatal outcomes. Sudden recurrence of PD or dystonia symptoms in patients 
treated by DBS can be potentially life-threatening, so scheduling the replacement of a discharged IPG battery should not be 
postponed. The COVID-19 pandemic should alert staff at emergency, neurology and movement disorders wards not to postpo-
ne the visits of patients with an implanted DBS system.
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Introduction
Deep brain stimulation (DBS) has become an established 
treatment option for patients with movement disorders in-
cluding Parkinson’s Disease (PD) and dystonia. In numerous 
clinical trials, DBS has shown improvement in quality of life, 
mobility in patients with advanced PD suffering bothersome 
motor fluctuations, treatment-resistant dyskinesias, the ma-
jority of non-motor symptoms, as well as motor symptoms of 
drug-resistant focal/segmental or generalised dystonia. DBS 
has been approved by the US Food and Drug Administration 
as an effective therapy for PD since 2002, and since 2003 for the 
treatment of dystonia [1–3]. Nevertheless, DBS implantation 
is associated with the possibility of both minor and major 
complications due to the implanted system [4, 5].
One possible side effect is the depletion of the implantable 
pulse generator (IPG) battery and the associated sudden re-
currence of PD or dystonia symptoms. These symptoms can be 
potentially life-threatening, so scheduling the replacement of 
a discharged IPG battery should not be postponed. During the 
COVID-19 pandemic, medical centres have postponed sched-
uled procedures, admitted only urgent cases in order to limit 
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the spread of Sars-CoV-2, and allocated hospital resources to 
control the pandemic [6, 7]. Patients with depleted batteries of 
DBS systems cannot wait, because the potential consequences 
of abrupt cessation of stimulation can be fatal, such as parkin-
sonism-hyperpyrexia syndrome, sudden akinesia with falls and 
bone fractures, venous thrombosis and pulmonary embolism 
or aspiration pneumonia in PD, and dystonic state in dystonia 
patients with rhabdomyolysis and renal failure.
Materials and methods
We searched the available literature using the PubMed, 
Scopus, EMBASE and Google Scholar databases for the 
keywords ‘deep brain stimulation’, ‘depletion’, ‘withdrawal’, 
‘battery exhaustion’, ‘hardware failure’, ‘Parkinson disease’ 
and ‘dystonia’ in various combinations. A total of 244 articles 
was found. The literature review included studies published 
from 1996 (i.e. from the introduction of DBS into clinical 
practice) to 2020 (31 December). The study did not include 
cases where brain stimulation was interrupted by infection of 
IPG system or electrodes, or for reasons other than discharge 
of the IPG battery. Papers were written in English, published 
as full-length texts. Abstracts as well as review papers were 
not included.
Results
We found a total of 244 articles, from which 12 met 
the established criteria. Selected papers presented a total of 
17 case reports of DBS-treated patients — 11 with PD, six 
with dystonia — who had depleted IPG batteries (Tab. 1, 2), 
who required urgent hospital admission. Ten patients with PD 
developed acute akinetic syndrome. Six of them were finally 
diagnosed with parkinsonism-hyperpyrexia syndrome (PHS), 
three had pulmonary embolism, deep vein thrombosis and 
aspiration pneumonia, and one had disseminated intravascu-
lar coagulation (DIC) and consequently multi-organ failure 
and death. One patient developed a coma as a result of IPG 
battery discharge. 2/11 patients with PD were reported during 
the COVID-19 pandemic. In the reported cases, the sudden 
recurrence of symptoms did not result from a reduction of 
oral antiparkinsonian treatment.
Among patients treated with DBS GPi for dystonia, six 
reports of IPG battery depletion and sudden motor deteriora-
tion were found (Tab. 2). Of these six patients, three developed 
acute dystonic state (two required urgent ICU admission - one 
patient developed cardio-respiratory failure and died despite 
intensive treatment, the other developed cardiopulmonary 
failure, rhabdomyolysis-related acute renal failure, and DIC as 
a result of dystonic state). 3/6 patients had dystonia symptoms 
worsening as a result of IPG battery depletion. Urgent battery 
replacement resulted in motor function improvement in two 
patients; one patient reported during the pandemic postponed 
their surgical procedure for financial reasons.
Discussion
The presented reports of PD and dystonia patients treated 
with DBS have shown that IPG battery depletion can result in 
fatal outcomes and must be avoided. 
This abrupt cessation of DBS function may be due to 
delayed or postponed outpatient visits. Two PD patients de-
scribed by Holla et al. had postponed follow-up visits due to 
the COVID-19 pandemic, resulting in IPG battery depletion 
and akinetic state [6]. COVID-19 may be a risk factor because 
many hospitals have limited access for ambulatory patients 
and also for planned surgeries. Patients, especially those with 
chronic diseases and co-morbidities, have avoided hospital 
and outpatient visits to protect themselves against infection. 
In some regions, a shortage of medical staff has also forced 
movement disorder neurologists to provide care for patients 
with COVID-19 [19]. 
In severe cases, where symptoms cannot be relieved with 
increased doses of oral or intravenous/subcutaneous/trans-
cutaneous medications and general treatment, an urgent IPG 
battery replacement should be performed. This was the only 
effective treatment in the majority of cases (Tab. 1, 2). The 
range of PD duration was in reported cases 12–22 years with 
long-lasting DBS therapy (3–14 years) and in such patients, 
the replacement of only pharmacological therapy instead of 
combined treatment with DBS is usually ineffective.
Parkinsonism-hyperpyrexia syndrome is one of the poten-
tially fatal complications in PD patients, most often occurring 
after a sudden reduction or discontinuation of antiparkinso-
nian medications, but also DBS battery depletion [20, 21]. 
This was a main complication in 5/11 patients (Tab. 1) and 
manifested itself as muscle stiffness, fever, impaired conscious-
ness, and dysautonomia. It is characterised by leukocytosis 
and elevated levels of creatine kinase (CK) in laboratory tests. 
The most common direct causes of death in patients with 
PHS are aspiration pneumonia, acute renal failure, deep vein 
thrombosis, pulmonary embolism, and DIC [22]. Neverthe-
less, akinetic-rigid state as the result of IPG battery depletion, 
reported in 6/11 PD cases, can also result in pneumonia, falls 
and bone fractures or head injuries, deep vein thrombosis 
with pulmonary embolism, and dysphagia with the risk of 
aspiration pneumonia, and should be recognised and treated 
vigorously. 
Dystonic state (DS), the main complication in 3/6 patients 
reported (Tab. 2), is characterised by muscle rigidity, muscle 
pain and fever. Muscle contractions involve also respiratory 
muscles and abdomen and lead to respiratory failure and 
hypoxaemia. Abnormal muscle contractions in the gastroin-
testinal tract can lead to dysphagia and aspiration pneumonia. 
Another potentially fatal complication of DS is rhabdomyolysis 
and acute renal failure [23]. Rapidly worsening symptoms are 
life-threatening. In patients with dystonia treated with DBS-
GPi, there have been reports of a dystonic state resulting in 
cardio-respiratory failure requiring hospitalisation in the ICU. 
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Table 1. Published PD cases with abrupt IPG battery depletion (in all patients bilateral STN was anatomical target)





Chou et al. [8] 63/M 17 years/4 years • Acute akinetic state
• Deep vein throm-
bosis, pulmonary 
embolism
• Oral levodopa treatment/no effect
• Inferior vena cava filter, anticoagulation treatment
• IPG battery replacement (5 days after hospital admission)/
improvement of motor function
76/M 14 years/3 years • Acute akinetic state • Oral levodopa treatment/ no effect 
• IPG battery replacement (a few days after motor function 
worsening)/improvement of motor function
Neuneier et 
al. [9]
77/M 18 years/5 years • PHS
• DIC
• Multi organ failure
• Oral levodopa treatment/ no effect
• Antibiotic therapy, fluid therapy, amantadine infusion, antipyre-
tic treatment/no effect
• IPG battery replacement (10 days after hospital admission)/no 
effect
• Death
Artusi et al. 
[10]
63/M 13 years/5 years • PHS • Fluid therapy, antipyretic therapy/general improvement 
• Oral levodopa treatment/no effect 
• IPG battery replacement (4 days after symptom onset)/impro-
vement of motor function 
R. Rajan et al. 
[11]
51/M 18 years/7 years • Acute akinetic state
• PHS
• Oral levodopa treatment, amantadine infusion/no effect 
• Fluid therapy, antipyretic treatment, antibiotic therapy/no 
effect
• IPG battery replacement (11 days after hospital admission)/
general and motor function improvement
54/F 22 years/11 years • Acute akinetic state
• Aspiration pneumo-
nia
• Oral levodopa treatment, pramipexol, amantadine infusion/no 
effect
• Antibiotic therapy, CPAP
• IPG battery replacement (8 days after hospital admission)/
general and motor function improvement
Liu et al. [12] 69/M 12 years/3 years • PHS • Antibiotic therapy, fluid therapy, antipyretic therapy/no effect
• Oral levodopa treatment, bromocriptine, dantrolen, benzodia-
zepine admission/no effect 
• IPG battery replacement (2 days after hospital admission)/
general and motor improvement 
Azar et al. 
[13]
67/F 23 years/7 years • PHS • Antibiotic therapy, B1 vitamin admission, fluid therapy/no 
effect 
• Oral levodopa treatment/ no effect 
• IPG battery replacement (17 days after hospital admission)/
general and motor improvement 
Kamel et 
al. [14]
73/M 21 years/14 years • Coma (GCS 4) • Oral levodopa treatment/no effect 
• IPG battery replacement (urgent surgery)/general improve-
ment 
Holla et al. [6] 67/M 17 years/4 years • Acute akinetic state • IPG battery replacement/motor function improvement 
60/F 17 years/4 years • Acute akinetic state • Oral levodopa treatment/minimal motor function improvement 
• IPG battery replacement/motor function improvement 
CPAP — continuous positive airway pressure; DIC — disseminated intravascular coagulation; GCS — Glasgow Coma Scale; IPG — internal pulse generator; PHS — parkinsonism hyperpyrexia syndrome
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Table 2. Published dystonia cases with abrupt IPG battery depletion 








Li et al. 
[15]


















• Mechanical ventilation circulatory 
support
• Dialysis therapy
• IPG battery replacement (1 day after 
hospital admission)/motor function 
improvement
Yanni et al. 
[18]
25/F Secondary dystonia/7 
years/2 years
GPi • Worsening symp-
toms of dystonia
• IPG battery replacement (urgent 
surgery at admission day)/motor 
function improvement
9/F Idiopathic dystonia/6 
years/2 years
GPi • Worsening symp-
toms of dystonia




33/M Idiopathic generalised 
dystonia/9 years/3 years
GPi • Worsening symp-
toms of dystonia
• Postponing procedure due to 
patient’s finances, optimising phar-
macological treatment
DIC — disseminated intravascular coagulation; DYT1 — early onset torsion dystonia; GPi — Internal Globus Pallidus; ICU — intensive care unit; IPG — internal pulse generator; PKAN — Pantothenate Kinase-
-Associated Neurodegeneration; STN — subthalamic nucleus; TD — tarditive dystonia 
In one case described, the battery was discharged and resulted 
in the death of the patient. Dystonic state should be treated as 
a neurological emergency and battery depletion has a worse 
prognosis in patients with dystonia than with PD: in PD pa-
tients with sudden DBS shutdown, symptoms can be partly 
relieved with increased doses of antiparkinsonian medications, 
while in dystonia patients there is no such emergency treat-
ment and the only effective treatment is battery replacement. 
Mitchel et al. analysed patient satisfaction with recharge-
able IPGs. Patient experience, especially those with dystonia, 
was positive, and they especially valued the fewer surgeries 
[24]. Considering the above, and the higher total electrical 
energy delivered and higher battery consumption in dystonia 
than in PD, the implantation of rechargeable batteries should 
be considered in every patient with dystonia treated with DBS.
Conclusions
This situation should warn medical staff at emergency, 
neurology and movement disorders wards against postponing 
the visits of patients with an implanted DBS system. Despite 
the progress and development of DBS technology, there are 
still no programmes or applications available for remote bat-
tery checking. Manufacturers of equipment for deep brain sti-
mulation should also ensure smooth delivery of the necessary 
elements of DBS systems, especially during a pandemic, to 
ensure constant access to depleted IPGs and shorten possible 
replacement delays. To avoid a sudden shutdown of DBS 
pacing due to battery depletion, battery status and electrical 
integrity may be checked through telemedicine or telephone 
consultation [7]. If the battery power is low, the elective pro-
cedure of IPG replacement should be planned and performed 
as soon as possible. One possible solution would be replacing 
IPG batteries as an outpatient procedure. To minimise the 
risk of sudden cessation of stimulation, reduction of amper-
age and frequency of the stimulation should be considered 
to reduce temporarily total electrical energy delivered and 
battery consumption [25]. 
Despite many years of practice of using DBS in patients with 
PD and dystonia, no studies including larger groups of patients 
with battery depletion were found in our search of databases. 
It is difficult to assess the percentage of patients with battery 
depletion, and the number appears to be underreported. Never - 
theless, all presented case reports are valuable and show the 
potentially fatal risks of delaying battery replacement. 
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